The next 10 years to see a voracity in Xerostomia (Dry Mouth) Treatment Market through digital transformation, reaching

Posted by Archit Sanjay on July 27th, 2022

With recorded sales worth US$ 952.7 Bn in 2021, the global xerostomia (dry mouth) treatment market is expected to experience high growth over the coming years owing to increasing consumption of prescribed medicines globally. The xerostomia treatment market is estimated to expand at a CAGR of nearly 6.1% from 2022 to 2032.

Xerostomia is commonly known as dry mouth that occurs as a result of decreased or missing saliva because of several clinical situations such as adverse effects of radioactivity on the neck and head, typically due to radiation therapy, undesirable effects of several drugs, or due to decreased functionality of the salivary glands. Heavy treatments such as chemotherapy and radiotherapy can make advanced cancer patients more susceptible to xerostomia.

Get a Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/17236

Globally, chronic diseases and conditions are on the rise. An aging population, as well as changes in societal behaviour, are all contributing to continuous increase in these widespread and expensive long-term health problems. Because population growth is predicted to be highest in developing countries, emerging markets will drive high market growth.

Growth in favourable compensation policies for xerostomia products together with increasing awareness and responsiveness about diseases related to the condition are some of the primary factors boosting market growth.

Company Profiles:

  • GlaxoSmithKline Plc
  • Daiichi Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc. (OraPharma)
  • ADVANZ PHARMA Corp. Limited
  • CCMed Ltd.
  • Elevate Oral Care, LLC
  • Orahealth Corporation
  • Forward Science
  • Parnell Pharmaceuticals, Inc
  • Cyclacel Pharmaceuticals, Inc.
  • Midatech Pharma Plc.
  • Perrigo Company Plc.
  • Entod International
  • Laboratories Kin, SA
  • ICPA HEALTH PRODUCTS Ltd
  • Biocosmetic Laboratories
  • The 3M Company
  • Mission Pharmacal Company
  • Chattem, Inc. (Sanofi)
  • Cipla Ltd.
  • Fresenius Kabi
  • Colgate-Palmolive Company
  • EUSA Pharma

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/17236

Key Takeaways from Market Study

  • Demand for oral sprays for xerostomia treatment is growing tremendously due to rising number of oral diseases. Demand for oral sprays is increasing as their prices are quite low and favourable reimbursement schemes, which further boost their sales and are expected to hold 32% market share in 2022.
  • Adults are at higher risk than paediatrics to xerostomia due to decreased salivary gland function. The adult segment is expected to account for a market share of around 90.4% in 2022.
  • Mail-order pharmacies are steadily growing due to the benefits offered by these pharmacies such as increased adherence to medication, home delivery, and special customer services. Thus, mail order pharmacies will hold the highest market share of 26.3% in 2022
  • The North America xerostomia treatment market will account for 32.7% of the total market share in 2022.

“Increased prevalence of xerostomia, rising use of prescription medicines, rise in radiotherapy & chemotherapy, and easy availability of over-the-counter medications will drive xerostomia treatment market growth over the coming years,” says an analyst of Persistence Market Research.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/17236

Market Competition

Key players in the xerostomia treatment market are adopting different strategies to reach targeted customers. They are advertising their brands through different channels such as promotion through healthcare providers such as dentists, oncologists, and other physicians, or in association with regional medical councils and international institutes.

Additionally, manufacturers are also focusing on collaborating with key R&D companies, reputable manufacturers, patent licensees & holders, government agencies, and prestigious universities for developing and commercializing new products based on patented and pioneered technologies.

  • For instance, in December 2018, GSK established a joint venture with Pfizer Inc. to establish a consumer healthcare company, which includes oral care products.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the xerostomia (dry mouth) treatment market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the product (oral sprays, oral solutions, oral liquids, gels, powders), age group (paediatric, adults {early adults (18-34 years), early middle age (35 – 44 years), late middle age (45 – 64 years), late adulthood (above 65+years)}), and end user (hospital pharmacies, retail pharmacies, drug stores, mail-order pharmacies, hypermarkets, and supermarkets), across seven key regions of the world.

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

Like it? Share it!


Archit Sanjay

About the Author

Archit Sanjay
Joined: April 12th, 2021
Articles Posted: 442

More by this author